Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.44 USD | -1.25% | -1.36% | -12.25% |
05-03 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
05-02 | Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.25% | 3.49B | |
+0.82% | 106B | |
+8.06% | 23.47B | |
-13.89% | 21.9B | |
-6.08% | 18.77B | |
-37.26% | 17.85B | |
-10.98% | 16.78B | |
+8.67% | 14.41B | |
+41.08% | 12.86B | |
+327.78% | 8.78B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- RBC Starts Ultragenyx Pharmaceutical at Outperform, Speculative Risk With $77 Price Target, Sees 'Particularly Attractive' Risk/Reward